## Summary

This paper evaluates small language models (SLMs) and small vision-language models (SVLMs) against larger medically-adapted models on clinical text summarization (MeQSum) and radiology report generation (MIMIC-CXR). The authors benchmark models across zero-shot, few-shot, and PEFT (LoRA) settings, and conduct a "collapse analysis" identifying a ~1B parameter safety threshold below which hallucination rates spike. The radiology experiment finds small VLMs still lag behind large VLMs even after fine-tuning.

## Strengths

- **The safety collapse analysis (Table 3) is a genuinely useful diagnostic.** The finding that hallucination rates spike from ~2–3% at 1.7B parameters to 18% (SmolLM2-360M) and 75% (Gemma-3-270M) is concrete and actionable for practitioners choosing deployment thresholds. The four-dimensional collapse framework (Task Adherence, Hallucination Rate, Concept Recall, Prompt Robustness) is more informative than relying on a single aggregate metric.

- **The radiology report generation comparison (Section 3.3, Table 4) is clean and transparently reported.** Small VLMs are fine-tuned on MIMIC-CXR, show improvement, but are honestly acknowledged to still trail large VLMs. The qualitative example in Figure 4 concretely illustrates the gap.

- **The four-metric evaluation suite (BLEU, ROUGE-L, BERTScore, MEDCON) is well-chosen**, capturing syntactic, semantic, and domain-specific clinical accuracy.

## Weaknesses

### Fatal
None.

### Major

- **Asymmetric fine-tuning comparison undermines the headline claim.** The paper's central claim—that small models "reach" and "occasionally exceed" much larger medical LLMs—rests primarily on Section 3.2 / Figure 3, where small LMs receive LoRA fine-tuning while the large LMs (BioMistral-7B, Med-LLaMA-8B, OpenBioLLM-8B) are evaluated only under ICL (zero/few-shot) with no LoRA results reported. The LoRA column for these large models is empty in Figure 3's table (lines 163–165 show "—"). The abstract, Results (line 231: "all small LMs outperformed large LMs across every metric"), and Discussion (line 247: "all small LMs outperformed large LMs across all metrics") all make this claim without flagging the asymmetry. This design does not answer whether small models can match large models when both are adapted equally—it answers the much weaker question of whether a fine-tuned 1B model can outperform an un-fine-tuned 8B model, which is neither surprising nor a fair test of the paper's thesis. The zero-shot results (Table 2), where both size classes are compared on equal footing, show SmolLM2 (1.7B) competitive on some metrics but not consistently exceeding large models (e.g., OpenBioLLM-8B has higher MEDCON 0.336 vs. 0.271; BioMistral has higher BLEU 0.0690 vs. 0.0464). This asymmetry is structural and cannot be resolved without either adding LoRA results for the large LMs or substantially reframing the claims.

### Minor

- **BERTScore inconsistency between Table 2 and Figure 3.** Table 2 reports LLaMA-3.2 (1B) zero-shot BERTScore as 0.7632 (~76.3%, averaged across 5 prompt templates). In Figure 3, the ICL (2-shot) BERTScore for Llama-3.2-16 (presumably the same model) is ~52.0% (line 172). The paper states that two-shot yields "modest gains (≈2–3%)" for LLaMA-3.2 (line 112), yet the displayed data shows a massive drop from ~76% to ~52%. This discrepancy is unexplained and undermines confidence in experimental consistency.

- **SmolLM3-3B appears in the collapse analysis (Table 3, line 126) without introduction.** This model is not listed in Table 1's model overview, not used in the zero-shot (Table 2) or fine-tuning (Figure 3) experiments, and its relationship to the SmolLM2 family used elsewhere is never explained. This raises questions about what exactly was evaluated in the collapse analysis.

- **No variance or statistical significance reported.** All results are point estimates on a 250-sample test set. Without confidence intervals, standard deviations across runs, or significance tests, it is unclear whether observed differences (e.g., the small-model advantages in fine-tuning) are reliable.

- **Text fine-tuning dataset is not described.** The paper mentions fine-tuning on "MeQ-Small corpus" (line 231) and "domain-specific summarization corpora" (line 247) but provides no details about its size, composition, or relationship to the MeQSum evaluation dataset, making the text fine-tuning results difficult to interpret or reproduce.

- **VLM comparison may have the same asymmetry.** Table 4 annotates small VLMs as "Fine-tuned" on MIMIC-CXR but does not specify whether the large VLMs (Med-Flamingo 9B, LLaVA-Med 7B) received equivalent fine-tuning or were evaluated zero-shot. Since the conclusion (small VLMs lag behind large ones) runs opposite to the asymmetry and is not overstated, this does not invalidate the finding but prevents assessing how much of the gap reflects model capacity vs. adaptation protocol.

### Trivial

- The contribution list mentions "Multidimensional Scaling Analysis" (line 21), but the paper performs no multidimensional scaling or dimensionality reduction—this is a misnomer for the cross-model benchmarking actually conducted.
- QLoRA and prompt tuning are mentioned as PEFT methods tried (line 120) but their results are not reported. Reporting them (even briefly as underperforming) would aid practitioners.

## Nice-to-Haves

- Fine-tuning the large LMs with the same LoRA recipe and comparing all models on equal footing would make the central claim credible.
- Tabulating the few-shot (2-shot) results that are currently only described qualitatively (line 112) would improve reproducibility.
- Specifying generation stopping criteria and output token limits would aid reproducibility.

## Removed Points

These points from the input review are removed; treat with caution:
- **"MeerKAT-8B is referenced but not included in experiments":** MeerKAT-8B appears only in the Related Work section (line 42) as a citation of prior work, not as a claimed experimental subject. Strawman criticism.
- **"Abstract lists 'Multidimensional Scaling Analysis' as a contribution":** Already demoted to Trivial above—it is a naming issue, not a substantive flaw.
- **Criticisms about missing appendix content or reference formatting:** These are parser artifacts that strip non-body sections; they are not author errors.

## Novel Insights

None beyond the paper's own contributions.

## Suggestions

1. **Reframe the contribution.** The paper's strongest evidence is the collapse analysis and the zero-shot competitiveness. Either run LoRA on the large LMs for a fair comparison, or explicitly reframe the fine-tuning result as "LoRA-tuned small model vs. ICL-only large model" and adjust the abstract accordingly.
2. **Resolve the BERTScore discrepancy** between Table 2 and Figure 3, and clarify whether Llama-3.2-16 is the same model as LLaMA-3.2 (1B) and why the scores differ so dramatically.
3. **Clarify the identity of SmolLM3-3B** and its relationship to the SmolLM2 family used elsewhere.
4. **Add confidence intervals or standard deviations** to all reported metrics.
5. **Describe the "MeQ-Small" corpus** used for text fine-tuning.

---

**Round 1 bracket:** 3.0–5.0

**Anchor papers (all rounds):**
- **8QTpYC4smR** (avg 1.00, Strong Reject): Systematic review with no experimental contribution — far weaker than the reviewed paper.
- **K1bv86Uvbp** (avg 3.00, Reject): LLMs for biomedical KG construction — less structured evaluation, narrower scope.
- **gpKEDj9Dgg** (avg 2.00, Reject): ASR+LLM for medication corpus — weaker experimental design.
- **jgVqCCg5XX** (avg 4.00, Reject): Scaling effects of LLMs in medicine — comparable quality; has a new benchmark but similar overclaim issues.
- **MEztAJjcYZ** (avg 4.25, Reject): Clinical note summarization with iterative reflexion — comparable; mixed reviews, method-driven contribution.
- **EQZMx8Lc0n** (avg 5.00, Reject): RoCoFT PEFT method — stronger methodological contribution.
- **BqHaLnans2** (avg 6.20, Accept): LLM-CXR for radiology — stronger methodological novelty and evaluation.
- **myZNJSpiK1** (avg 6.75, Reject): CoVT-CXR — stronger dataset contribution and evaluation.
- **ZLAQ6Pjf9y** (avg 5.60, Reject): SAE-Rad — stronger method novelty, weaker than typical accept.
- **f4gF6AIHRy** (avg 8.00, Accept): Data selection for LLM pre-training — fundamentally different type of contribution, much stronger.

The reviewed paper has genuine empirical value (collapse analysis, zero-shot comparisons, transparent VLM results) that places it above strong rejects (~1.0). However, the asymmetric comparison that supports the headline claim is a structural weakness that prevents it from reaching borderline-accept territory (~5.5+). It is most comparable to the ~3.5–4.5 anchors (jgVqCCg5XX at 4.0, MEztAJjcYZ at 4.25), which have similar profiles of useful content undermined by overclaimed findings or evaluation gaps.

MY FINAL SCORE: <score>3.5</score>
MY FINAL DECISION: <decision>Reject</decision>